PLGA nanoparticle-encapsulated lysostaphin for the treatment of Staphylococcus aureus infections

Area of Science:

• Microbiology
• Biotechnology
• Materials Science

Background:

• Staphylococcus aureus, particularly methicillin-resistant strains (MRSA), causes severe infections with high mortality.
• Existing treatments face challenges like antibiotic resistance and limited efficacy.
• Lysostaphin shows potent anti-staphylococcal activity but has limitations in clinical use.

Purpose of the Study:

• To develop and evaluate polylactic-co-glycolic acid (PLGA) nanoparticles for encapsulating lysostaphin.
• To assess the enhanced antimicrobial efficacy of lysostaphin-loaded PLGA nanoparticles against Staphylococcus aureus.
• To investigate the effectiveness of these nanoparticles in planktonic, biofilm, and intracellular infection models.

Main Methods:

• Lysostaphin was encapsulated within biodegradable PLGA nanoparticles.
• Antimicrobial activity was tested against various Staphylococcus aureus strains, including GFP-expressing strains for traceability.
• Efficacy was evaluated in planktonic, biofilm, and in vitro intracellular infection models.

Main Results:

• Lysostaphin-loaded PLGA nanoparticles demonstrated significant bacterial viability reduction in planktonic and biofilm states.
• The nanoparticles showed enhanced efficacy in an in vitro intracellular infection model compared to free lysostaphin.
• Successful encapsulation and sustained release properties of PLGA nanoparticles were observed.

Conclusions:

• PLGA nanoparticle encapsulation enhances the therapeutic potential of lysostaphin against Staphylococcus aureus.
• This novel delivery system overcomes limitations of free lysostaphin, offering a promising strategy for treating staphylococcal infections.
• The developed nanoparticles show potential for improved treatment of both extracellular and intracellular S. aureus infections.